Cervical screening

Lore & Background

Cervical screening procedures involve collecting a sample of cells from the cervix using a spatula or small brush, inserted via a speculum. Self-collection is an option for HPV testing and is as accurate as provider-collected samples, though this equality has not been demonstrated for Pap smears or liquid-based cytology. The collected cells are examined for abnormalities, with molecular tests identifying high-risk human papillomavirus (HPV) strains, which cause nearly all cervical cancers.

Reader's Guide

Cervical screening is significant because it allows for early detection and treatment of precancerous lesions and early-stage cancer, reducing mortality. Disparities in access to screening are reflected in higher cervical cancer rates among minority groups in higher-income countries and in lower-income global regions, where 80% of cases occur. The World Health Organization recommends HPV molecular testing as primary screening every 5 to 10 years, starting at age 30 and stopping at age 50 if recent tests are negative. Recent studies show that health belief model factors, such as self-efficacy and knowledge, are associated with higher screening rates, while socioeconomic barriers lower uptake. Social media platforms are being used to disseminate screening information to encourage participation.

Did You Know?

• HPV testing can identify up to 14 different high-risk strains of the virus.
• Most women clear HPV infections within 18 months; prolonged infection with high-risk types increases cervical cancer risk.
• Visual inspection involves applying acetic acid or Lugol's iodine to highlight abnormal areas.
• Co-testing combines HPV testing and cytology to calculate immediate risk for CIN3+.

The Virus at the Root

Nearly every case of cervical cancer—roughly 99 percent—traces back to a persistent genital infection with human papillomavirus. Of the more than 200 known HPV types, twelve are classified as high-risk, with types 16 and 18 alone responsible for about three-quarters of all cervical cancers worldwide. The mechanism is now well understood: high-risk strains can splice their genetic material into the host cell's DNA, triggering production of two viral proteins, E6 and E7. E6 dismantles the tumor-suppressing protein p53, while E7 inactivates pRb. Together, their loss unleashes uncontrolled cell growth, abnormal blood-vessel formation, and disrupted cell-cycle regulation. Most squamous cell carcinomas (around 75 percent of cases) are linked to HPV 16, while the adenocarcinoma subtype (20–25 percent) is more often tied to HPV 18. The transformation from initial infection to invasive cancer typically unfolds over a decade or two, giving a long window for intervention. Additional risk multipliers include smoking, which roughly doubles or triples invasive-cancer incidence among HPV-positive women, as well as co-infections with HIV or other sexually transmitted organisms that further weaken the body's ability to clear the virus.

Vaccination and the Power of Screening

The most cost-effective public-health intervention against cervical cancer is HPV vaccination. Available vaccines shield against two to seven high-risk viral strains and, when widely adopted, can avert up to 90 percent of cervical cancers. By the close of 2024, 147 countries had incorporated the vaccine into their national immunization schedules for girls, and 47 had extended coverage to boys as well. Yet because no vaccine covers every oncogenic type, clinical guidelines still call for routine cervical screening. Screening is uniquely powerful because it can identify precancerous cellular changes while they are still reversible; treating those early abnormalities prevents cancer from ever taking hold. In high-income nations, the sustained rollout of organized screening programs has already produced dramatic declines in cervical-cancer incidence and mortality. The combination of vaccination for prevention and periodic screening for early detection therefore forms a two-pronged strategy: one stops the virus before it establishes a foothold, and the other catches the damage before it becomes irreversible. Together, they represent the closest thing medicine has to a complete elimination pathway for this disease.

A Global Inequity

Cervical cancer ranks as the fourth most common cancer and the fourth leading cancer-related killer among women worldwide. In 2022 alone, more than 660,000 new diagnoses were recorded and approximately 350,000 women lost their lives to the disease, accounting for roughly 8 percent of all cancer cases and deaths. The distribution of that burden is starkly unequal: nearly 90 percent of both cases and fatalities occur in low- and middle-income countries. In those settings, cervical cancer constitutes 17 percent of all female cancer diagnoses, compared with just 2 percent in high-income nations. This gap reflects limited access to screening infrastructure, HPV vaccination, and timely treatment. In response, the World Health Organization launched a Global Strategy to accelerate the elimination of cervical cancer as a public-health problem on 17 November 2020, a resolution endorsed by 194 member states. That date is now observed annually as Cervical Cancer Elimination Day of Action, serving as a reminder that the tools to end this disease exist but remain unevenly distributed across the globe.

From Silent Onset to Treatment

In its earliest stages, cervical cancer is typically silent—no symptoms alert the patient or the clinician. As the disease progresses, warning signs may emerge: unusual vaginal bleeding, pain during intercourse, pelvic discomfort, or an abnormal discharge. In locally advanced disease, the tumor can invade neighboring pelvic structures, producing leg swelling, blood clots, kidney enlargement with flank pain, rectal or urinary bleeding, and even leakage of urine or feces through the vagina. Diagnosis usually begins with a cervical screening test that flags suspicious cells, followed by a biopsy for histological confirmation. Medical imaging then maps whether the cancer has spread beyond the cervix into the abdomen, lungs, or other organs. Treatment is tailored to stage and may combine surgery, chemotherapy, radiation therapy, and immunotherapy. Five-year survival in the United States stands at about 69 percent, but that figure swings widely depending on how early the cancer is caught. The legacy of cervical-cancer research also extends beyond the clinic: the immortalized HeLa cell line, derived from the cells of Henrietta Lacks, remains one of the most widely used biological tools in medical science.